Semaglutide may cause delayed stomach emptying when doses increase quickly in a diabetic patient

Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. East Alabama Medical Centre issued approval N/A. The consent was provided voluntarily and with full understanding of the nature and purpose of the case report, titled "Unmasking Semaglutide-Induced Gastroparesis: The Dangers of Rapid Dose Escalation in a Diabetic Patient". Verbal consent was obtained via phone and has been appropriately documented. All necessary privacy and confidentiality protections have been observed in accordance with ethical guidelines. The physician, Dr. Kevin Wortman II, DO, has confirmed the discussion and understanding with the patient, and both the patient and physician have signed and dated the consent form. This research activity, including case documentation and reporting, has been reviewed and approved under the supervision of the Department of Internal Medicine Residency of the East Alabama Medical Centre. No financial compensation or coercion was involved in obtaining consent, and participation in the case report does not affect the quality of care provided to the patient. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.